Panacela Labs, Inc. is a joint venture company founded in 2011 by Cleveland BioLabs (NASDAQ:CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs and Open Joint Stock Company “Rusnano” in conjunction with Roswell Park Cancer Institute, Children’s Cancer Institute Australia and Cleveland Clinic Foundation. Panacela is 66.77% owned by Cleveland BioLabs.
The Company’s lead development program is Mobilan, a nanoparticle-formulated, recombinant non-replicating adenovirus in clinical development as a universal cancer therapy.
News and Events
Cleveland Biolabs (NASDAQ:CBLI) today announced that through a series of transactions and in cooperation with Open Joint Stock Company RUSNANO (Rusnano) it has recapitalized Panacela Labs, Inc. (Panacela), a majority-owned joint venture.
This section will include future events, organized by Panacela Labs.